SEARCH

SEARCH BY CITATION

References

  • Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 26152622.
  • An, B., Goldfarb, R.H., Siman, R. & Dou, Q.P. (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death and Differentiation, 5, 10621075.
  • Balbasubramanian, S., Crowley, S., Sirisiwad, M., Thiemann, P., Chen, J. & Buggy, J. (2011) The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-{kappa}B pathways. Blood (ASH annual Meeting Abstracts), 117, 4969.
  • Bea, S., Zettl, A., Wright, G., Salaverria, I., Jehn, P., Moreno, V., Burek, C., Ott, G., Puig, X., Yang, L., Lopez-Guillermo, A., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Gascoyne, R.D., Connors, J.M., Grogan, T.M., Braziel, R., Fisher, R.I., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Simon, R., Powell, J., Wilson, W.H., Jaffe, E.S., Montserrat, E., Muller-Hermelink, H.K., Staudt, L.M., Campo, E. & Rosenwald, A. (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 106, 31833190.
  • Bedford, L., Lowe, J., Dick, L.R., Mayer, R.J. & Brownell, J.E. (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature reviews. Drug discovery, 10, 2946.
  • Castillo, J.J., Furman, M. & Winer, E.S. (2012) CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs, 21, 1522.
  • Celeste, A., Petersen, S., Romanienko, P.J., Fernandez-Capetillo, O., Chen, H.T., Sedelnikova, O.A., Reina-San-Martin, B., Coppola, V., Meffre, E., Difilippantonio, M.J., Redon, C., Pilch, D.R., Olaru, A., Eckhaus, M., Camerini-Otero, R.D., Tessarollo, L., Livak, F., Manova, K., Bonner, W.M., Nussenzweig, M.C. & Nussenzweig, A. (2002) Genomic instability in mice lacking histone H2AX. Science, 296, 922927.
  • Chen, K.F., Yeh, P.Y., Yeh, K.H., Lu, Y.S., Huang, S.Y. & Cheng, A.L. (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Research, 68, 66986707.
  • Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 2755.
  • Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., Bhagat, G., Chadburn, A., Dalla-Favera, R. & Pasqualucci, L. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature, 459, 717721.
  • Craxton, A., Jiang, A., Kurosaki, T. & Clark, E.A. (1999) Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. Journal of Biological Chemistry, 274, 3064430650.
  • Dai, Y., Rahmani, M. & Grant, S. (2003) Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene, 22, 71087122.
  • Dai, Y., Rahmani, M., Dent, P. & Grant, S. (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Molecular and Cellular Biology, 25, 54295444.
  • Dasmahapatra, G., Lembersky, D., Rahmani, M., Kramer, L., Friedberg, J., Fisher, R.I., Dent, P. & Grant, S. (2009) Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology & Therapy, 8, 808819.
  • Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R.I., Friedberg, J., Dent, P. & Grant, S. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood, 115, 44784487.
  • Dasmahapatra, G., Lembersky, D., Son, M.P., Attkisson, E., Dent, P., Fisher, R.I., Friedberg, J.W. & Grant, S. (2011) Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics, 10, 16861697.
  • Dasmahapatra, G., Lembersky, D., Son, M.P., Patel, H., Peterson, D., Attkisson, E., Fisher, R.I., Friedberg, J.W., Dent, P. & Grant, S. (2012) Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Molecular Cancer Therapeutics, 11, 11221132.
  • Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. & Greenberg, M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91, 231241.
  • Datta, S.R., Brunet, A. & Greenberg, M.E. (1999) Cellular survival: a play in three Akts. Genes & Development, 13, 29052927.
  • Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 8892.
  • Dunleavy, K., Pittaluga, S., Czuczman, M.S., Dave, S.S., Wright, G., Grant, N., Shovlin, M., Jaffe, E.S., Janik, J.E., Staudt, L.M. & Wilson, W.H. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood, 113, 60696076.
  • Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de, V.S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 48674874.
  • Gao, N., Rahmani, M., Dent, P. & Grant, S. (2005) 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene, 24, 37973809.
  • Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667675.
  • Harrison, C. (2012) Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nature reviews. Drug discovery, 11, 96.
  • Herman, S.E., Gordon, A.L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K.A., Buggy, J.J., Hamdy, A., Johnson, A.J. & Byrd, J.C. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117, 62876296.
  • Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N.C., Richardson, P.G., Carrasco, R.D. & Anderson, K.C. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 114, 10461052.
  • Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 1307513080.
  • Hu, J., Dang, N., Menu, E., De, B.E., Xu, D., Van, C.B., Van, V.E. & Vanderkerken, K. (2012) Activation of ATF4 mediates the unwanted Mcl-1 accumulation by proteasome inhibition. Blood, 119, 82637.
  • Hussain, A., Yu, L., Faryal, R., Mohammad, D.K., Mohamed, A.J. & Smith, C.I. (2011) TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. FEBS Journal, 278, 20012010.
  • Ikeda, H., Hideshima, T., Fulciniti, M., Perrone, G., Miura, N., Yasui, H., Okawa, Y., Kiziltepe, T., Santo, L., Vallet, S., Cristea, D., Calabrese, E., Gorgun, G., Raje, N.S., Richardson, P., Munshi, N.C., Lannutti, B.J., Puri, K.D., Giese, N.A. & Anderson, K.C. (2010) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood, 116, 14601468.
  • Jia, L., Gopinathan, G., Sukumar, J.T. & Gribben, J.G. (2012) Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PLoS One, 7, e32584.
  • Jung, H.J., Chen, Z., Fayad, L., Wang, M., Romaguera, J., Kwak, L.W. & McCarty, N. (2012) Bortezomib-resistant nuclear factor kappaB expression in stem-like cells in mantle cell lymphoma. Experimental Hematology, 40, 107118.
  • Khalil, A.M., Cambier, J.C. & Shlomchik, M.J. (2012) B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science, 336, 11781181.
  • Kim, A.H., Khursigara, G., Sun, X., Franke, T.F. & Chao, M.V. (2001) Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Molecular and Cellular Biology, 21, 893901.
  • Kim, A., Park, S., Lee, J.E., Jang, W.S., Lee, S.J., Kang, H.J. & Lee, S.S. (2012) The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leukemia Research, 36, 912920.
  • Lam, L.T., Davis, R.E., Pierce, J., Hepperle, M., Xu, Y., Hottelet, M., Nong, Y., Wen, D., Adams, J., Dang, L. & Staudt, L.M. (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clinical Cancer Research, 11, 2840.
  • Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., Shokat, K.M., Lavail, M.M. & Walter, P. (2007) IRE1 signaling affects cell fate during the unfolded protein response. Science, 318, 944949.
  • Ling, Y.H., Liebes, L., Zou, Y. & Perez-Soler, R. (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. Journal of Biological Chemistry, 278, 3371433723.
  • Lopez-Guerra, M. & Colomer, D. (2010) NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Expert opinion on therapeutic targets, 14, 275288.
  • Mohamed, A.J., Yu, L., Backesjo, C.M., Vargas, L., Faryal, R., Aints, A., Christensson, B., Berglof, A., Vihinen, M., Nore, B.F. & Smith, C.I. (2009) Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunological Reviews, 228, 5873.
  • Mujtaba, T. & Dou, Q.P. (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discovery medicine, 12, 471480.
  • Nencioni, A., Grunebach, F., Patrone, F., Ballestrero, A. & Brossart, P. (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia, 21, 3036.
  • Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, W.J. Jr, Lee, K.P. & Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 49074916.
  • O'Brien, S., Buger, J.A., Blum, K.A., Furman, R.R., Coutre, S.E., Sharman, J., Flinn, I.W., Grant, B., Heerema, N.A., Johnson, A.J., Navarro, T., Holmgren, E., Hedrick, E. & Byrd, J.C. (2011) The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): follow-up of a Phase Ib/II Study. Blood (ASH annual Meeting Abstracts), 118, 983.
  • Orlowski, R.Z., Small, G.W. & Shi, Y.Y. (2002) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277, 2786427871.
  • Rahmani, M., Davis, E., Crabtree, T., Habibi, J., Nguyen, T., Dent, P. & Grant, S. (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of ER stress. Molecular and Cellular Biology, 27, 54995413.
  • Rawlings, D.J., Scharenberg, A.M., Park, H., Wahl, M.I., Lin, S., Kato, R.M., Fluckiger, A.C., Witte, O.N. & Kinet, J.P. (1996) Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science, 271, 822825.
  • Richardson, P.G., Mitsiades, C., Hideshima, T. & Anderson, K.C. (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annual Review of Medicine, 57, 3347.
  • Staudt, L.M. & Dave, S. (2005) The biology of human lymphoid malignancies revealed by gene expression profiling. Advances in Immunology, 87, 163208.
  • Staudt, L., Dunleavy, K., Buggy, J., Hedrick, E., Lucas, N., Pittaluga, S., Javar, S., Schmidt, R., Williams, M., Lih, J., Jaffe, E. & Wilson, W. (2011) The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL. Blood (ASH annual Meeting Abstracts), 118, 2716.
  • Stommel, J.M., Kimmelman, A.C., Ying, H., Nabioullin, R., Ponugoti, A.H., Wiedemeyer, R., Stegh, A.H., Bradner, J.E., Ligon, K.L., Brennan, C., Chin, L. & DePinho, R.A. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287290.
  • Takada, Y. & Aggarwal, B.B. (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. Journal of Biological Chemistry, 279, 47504759.
  • Teske, B.F., Wek, S.A., Bunpo, P., Cundiff, J.K., McClintick, J.N., Anthony, T.G. & Wek, R.C. (2011) The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Molecular Biology of the Cell, 22, 43904405.
  • Toulany, M., Kasten-Pisula, U., Brammer, I., Wang, S., Chen, J., Dittmann, K., Baumann, M., Dikomey, E. & Rodemann, H.P. (2006) Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clinical Cancer Research, 12, 41194126.
  • Wang, L., Martin, P., Blum, K., Kahl, B., Maeda, L., Advani, R., Williams, M., Rule, S., Rodriguez, S., Pang, C., Hedrick, E. & Goy, A. (2011) The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously treated mantle cell lymphoma: preliminary results of a phase II trial. Blood (ASH annual Meeting Abstracts), 118, 442.
  • Weniger, M.A., Rizzatti, E.G., Perez-Galan, P., Liu, D., Wang, Q., Munson, P.J., Raghavachari, N., White, T., Tweito, M.M., Dunleavy, K., Ye, Y., Wilson, W.H. & Wiestner, A. (2011) Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clinical Cancer Research, 17, 51015112.
  • Wickremasinghe, R.G., Prentice, A.G. & Steele, A.J. (2011) Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets. British Journal of Haematology, 153, 545556.
  • Williams, M.E., Connors, J.M., Dreyling, M.H., Gascoyne, R.D., Kahl, B.S., Leonard, J.P., Press, O.W. & Wilson, W.H. (2011) Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukaemia & Lymphoma, 52, 2433.
  • Xu, C., Bailly-Maitre, B. & Reed, J.C. (2005) Endoplasmic reticulum stress: cell life and death decisions. The Journal of clinical investigation, 115, 26562664.
  • Yeramian, A., Sorolla, A., Velasco, A., Santacana, M., Dolcet, X., Valls, J., Abal, L., Moreno, S., Egido, R., Casanova, J.M., Puig, S., Vilella, R., Llombart-Cussac, A., Matias-Guiu, X. & Marti, R.M. (2012) Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International Journal of Cancer, 130, 967978.
  • Yu, C., Rahmani, M., Dent, P. & Grant, S. (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Experimental Cell Research, 295, 555566.